PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support - Concepedia

Concepedia

Publication | Open Access

PDE5A Inhibitor Treatment of Persistent Pulmonary Hypertension After Mechanical Circulatory Support

DOI Full Paper Access

185

Citations

35

References

2008

Year

Ryan J. Tedford, Anna R. Hemnes, Stuart D. Russell, Ilan S. Wittstein, Mobusher Mahmud, Ari Zaiman, Stephen C. Mathai, David R. Thiemann, Paul M. Hassoun, Reda E. Girgis,

Circulation Heart Failure

Abstract

In patients with persistent PH after recent LVAD placement, phosphodiesterase type 5A inhibition in this open-label trial resulted in a significant decrease in PVR when compared with control patients.

References

	Year	Citations
Heart Disease: A Textbook of Cardiovascular Medicine. Annals of Internal Medicine HypertensionHeart FailureHeart DiseasePreventive CardiologyStructural Heart Disease	1984	4.1K
Tricuspid Annular Displacement Predicts Survival in Pulmonary Hypertension Paul R. Forfia, Micah R. Fisher, Stephen C. Mathai, American Journal of Respiratory and Critical Care Medicine	2006	1.1K
Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Eiki Takimoto, Hunter C. Champion, Manxiang Li, Nature Medicine Cardiac MuscleCardiomyopathyMolecular PhysiologyCardiovascular DiseaseBiochemistry	2005	894
Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute Inhibition of Phosphodiesterase Type 5 Improves Contractility Jayan Nagendran, Stephen L. Archer, Daniel Soliman, Circulation	2007	526
The Registry of the International Society for Heart and Lung Transplantation: Seventeenth Official Report—2000 Jeffrey D. Hosenpud, Leah E. Bennett, Berkeley M Keck, The Journal of Heart and Lung Transplantation Lung TransplantationTransplantation SurgeryTransplantationSeventeenth Official Report—2000Cardiopulmonary Transplantation	2000	460
Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: Testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group Angelika Costard‐Jäckle, Michael B. Fowler Journal of the American College of Cardiology HypertensionPulmonary Arterial HypertensionCardiovascular DiseaseHigh Risk GroupPotential Reversibility	1992	414
Secondary Pulmonary Hypertension in Chronic Heart Failure Denzil Moraes, Wilson S. Colucci, Michael M. Givertz Circulation	2000	400
Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure Gregory D. Lewis, Justine Lachmann, Janice Camuso, Circulation	2006	347
Pulmonary Vascular Remodeling in Pulmonary Hypertension Due to Chronic Heart Failure Juan F. Delgado, Esther Conde, Violeta Sánchez, European Journal of Heart Failure	2005	284
Time course of resolution of pulmonary hypertension and right ventricular remodeling after orthotopic cardiac transplantation. Satinder J.S. Bhatia, James M. Kirshenbaum, Richard J. Shemin, Circulation Transplantation ProcedureLung TransplantationHypertensionHeart FailureRight Ventricular	1987	202

Page 1